Shinevia accelerates transition to comprehensive surgical solutions with ThinkTry acquisition

Jinan Shinevia Technology Co., Ltd. ("Shinevia"), a provider of specialized optical imaging technology solutions, has officially announced the strategic acquisition of Shenzhen ThinkTry Medical Co., Ltd. ("ThinkTry"). Following this transaction, Shinevia will accelerate its strategic transition from a specialized optical imaging solutions provider to a comprehensive surgical solutions provider. This move will establish a product portfolio encompassing medical imaging products, innovative surgical instruments, minimally invasive surgical devices, and complementary consumables, enabling more efficient delivery of surgical products and innovative solutions to healthcare professionals.

Shinevia was established in 2017 in the High-tech Zone of Jinan, Shandong Province, and has since garnered numerous honors including the National "Little-Giant" Enterprise, National High-tech Enterprise, Shandong Provincial Specialized, Refined, Distinctive, and New (SRDN) Enterprise, Jinan Municipal SRDN Enterprise, and Jinan Gazelle Enterprise recognitions. The company operates two Shandong Provincial Engineering Technology Centers—focused on laparoscopic engineering technology and embodied robotics—along with the Jinan Key Laboratory for Special Optical Imaging Technology. To date, Shinevia has been granted over 130 patents, with its patent portfolio ranking among the industry leaders in its specialized segments.

ThinkTry Medical was founded in 2019 with a dedicated focus on the research and development of minimally invasive surgical medical devices. In 2023, the company secured two Class III medical device registration certificates from China's NMPA: a Breast Lesion Rotation Biopsy System (NMPA Registration No. 20233011552) for rotational biopsy sampling of abnormal breast tissue, and an Ultrasonic Soft Tissue Cutting and Hemostasis Device (commonly known as an ultrasonic scalpel, NMPA Registration No. 20233011557). Both products have now been successfully included in China's centralized procurement catalog and have been adopted for clinical use in over 100 hospitals.

Post-acquisition, Shinevia and ThinkTry will strengthen cooperation through product-line expansion and channel synergies. ThinkTry will enhance Shinevia's product range, while Shinevia will accelerate ThinkTry's energy-surgical platform development. Their complementary sales networks will jointly drive market growth.